Raiffeisen Bank International AG Sells 5,777 Shares of IQVIA Holdings Inc. $IQV

Raiffeisen Bank International AG trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 47.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,500 shares of the medical research company’s stock after selling 5,777 shares during the quarter. Raiffeisen Bank International AG’s holdings in IQVIA were worth $1,256,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IQV. BlackRock Inc. bought a new position in IQVIA during the 2nd quarter valued at approximately $2,811,292,000. Boston Partners purchased a new stake in shares of IQVIA in the 3rd quarter worth approximately $676,698,000. Norges Bank purchased a new stake in shares of IQVIA in the fourth quarter worth $497,445,000. Victory Capital Management Inc. increased its stake in IQVIA by 2,628.1% during the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after purchasing an additional 1,614,063 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of IQVIA during the second quarter valued at approximately $240,911,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Down 1.6%

IQV opened at $267.34 on Friday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The stock’s 50 day moving average price is $230.54 and its 200-day moving average price is $192.66. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $271.80. The stock has a market cap of $44.00 billion, a price-to-earnings ratio of 33.17, a P/E/G ratio of 2.29 and a beta of 1.18.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period last year, the company posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

Insider Buying and Selling

In other news, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the sale, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider W. Richard Staub sold 5,500 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 15,581 shares of company stock valued at $3,796,021 in the last 90 days. 1.70% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms recently issued reports on IQV. Morgan Stanley reaffirmed an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Robert W. Baird raised their price objective on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research note on Thursday, July 9th. Finally, Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $243.62.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.